| Objective:To observe the change of serum Estrogen(E2)in breast cancer patients with adjuvant therapy with tamoxifen(TAM) and toremifene(TOR),and the sequential adverse effect then to explore its mechanism, to provide a more accurate choice for clinical adjuvant endocrine therapy.Methods:To measure the level of seurm E2 and follicle-stimulating hormone (FSH) in breast cancer patients with tamoxifen and toremifene treatment and detect the ovaries by sonography if the serum E2 beyound the normol level.Results:With TAM treatment, E2 were increased in 17 cases (17.5%) among 97 cases. Ovarian cysts were detected in 8 patients(47.1%).There no relationship were found between both TAM and E2 with FSH; With TOR treatment, E2 were increased in 9 cases (42.9%) among 21 cases. Ovarian cysts were detected in 1 patient (11.1%), whose E2 increased also.There no relationship were found between both tamoxifen and E2 with FSH.Conclusion:The elevation of E2 may be caused by the effect on follicle cells by TAM and TOR.Ovarian cysts also may be the severe effect by TAM and TOR. These may be one of the appearance of estrogen-like effect and drug resistance of TAM and TOR. According to the results we Conclude that serum E2 should be routinely measured in young patients, in particular less than 50 years of age, with TAM and TOR treatment and ovarian cysts should be detected in those with higher E2(>600 pg/ml) and TAM or TOR should be replaced by other endocrine therapy or not be used in those with severely higher E2 or ovarian cysts. |
PDF Full Text Request